title: Alleviating the storm: ruxolitinib in HLH.
abstract: In this issue of Blood, Das and colleagues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murine models of hemophagocytic lymphohistiocytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).
authors.affiliation: UNIVERSITÄTSKLINIKUM JENA.
authors.forename: Paul
authors.identifier: http://orcid.org/0000-0002-6758-7809
authors.initials: P
authors.lastname: La Rosée
mesh_terms: D000818:Animals; D007249:Inflammation / Q000517:prevention & control*; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D008213:Lymphocyte Activation / Q000187:drug effects*; D051359:Lymphohistiocytosis, Hemophagocytic / Q000235:genetics* / Q000473:pathology*; D011720:Pyrazoles / Q000494:pharmacology*
chemical_list: D011720:Pyrazoles; D053612:Janus Kinases